CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome
Status:
Withdrawn
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
This is a phase 1/2 study of the combination of CPI-613 and hydroxychloroquine for the
treatment of high risk myelodysplastic syndrome patients who have failed a hypomethylating
agent.